Lupus & Connective Tissue Diseases
From the Journals
ASSET extension supports abatacept as treatment for diffuse cutaneous systemic sclerosis
“Exploratory outcome measures during the [6-month] open-label extension, including the composite ACR CRISS score,...
Conference Coverage
Switching to riociguat effective for some patients with PAH not at treatment goal
The clinical benefit of the switching to the sGC inhibitor was consistent across patient subgroups in the phase 4 REPLACE study.
Feature
Novel study explores link between primary immunodeficiencies, rheumatic diseases
Fully 48% of patients with autoimmune rheumatic diseases who developed persistent hypogammaglobulinemia after initiating treatment with...
Conference Coverage
Selexipag has no effect on daily activity in PAH patients
After 24 months of daily tracking, there was no benefit to increased daily activity for patients taking this drug.
News from the FDA/CDC
Systemic sclerosis patients share their perspectives and needs in treatment trials
FDA officials and clinical researchers heard about the impact that different symptoms have on patients’ daily lives in order to design better...
From the Journals
Low IgA levels associated with increased infection risk in SLE patients
“This is the first dedicated study to examine the relationship between acquired low immunoglobulins and infection risk in adult patients with SLE...
From the Journals
New lupus classification criteria perform well in children, young adults
A new study upholds the accuracy of the 2019 ACR-EULAR classification criteria in patients aged 21 years and younger.
Conference Coverage
Dr. Len Calabrese gives advice on vaccinating adult patients with rheumatic disease
He highlights safety protocols and advises on recommended vaccines in rheumatology practice.
From the Journals
Role of aspirin explored in primary prevention of CVD in systemic rheumatic diseases
“The message for rheumatologists is it needs to be prescribed on an individual basis, rather than based on diagnosis of a rheumatic condition – at...
Conference Coverage
Promising drugs line up for lupus treatment
Lupus drugs in late-stage development seek to address unmet needs, notably in lupus nephritis.
From the Journals
Late-onset neutropenia more common than expected in patients on rituximab
“Even though most [cases] are incidental and can be self-limiting, some can be severe and associated with sepsis.”